Citation Impact
Citing Papers
Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure
2007
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
Clinician’s Guide to Prevention and Treatment of Osteoporosis
2014 Standout
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
2017 Standout
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
2004
Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>
2003 Standout
Child abuse: Adolescent records vs. adult recall
1990 Standout
Health benefits of physical activity: the evidence
2006 Standout
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
2010
Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus
2009
Modified intention to treat reporting in randomised controlled trials: systematic review
2010
Osteoporosis
2019 Standout
Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
2012
Elastomeric high‐mineral content hydrogel‐hydroxyapatite composites for orthopedic applications
2008 StandoutNobel
Osteoporosis
2006
Use of Bisphosphonates to Improve the Durability of Total Joint Replacements
2006
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
1999 Standout
Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial
2012
Effects of Continuing or Stopping Alendronate After 5 Years of Treatment
2006
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
2006 Standout
Diagnosis of osteoporosis and assessment of fracture risk
2002 Standout
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Preventing fractures in elderly people
2003
Clinical Assessment of Bone Mass, Quality and Architecture
1999
Comparison of Microcomputed Tomographic and Microradiographic Measurements of Cortical Bone Porosity
2004
Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term Extension
2004
Impracticability of Informed Consent in the Registry of the Canadian Stroke Network
2004 Standout
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis
2004
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
2006 Standout
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
2007
Osteoporosis: now and the future
2011 Standout
Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study
2002
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
2004
Is the paradigm shifting?
2003
Skeletal remodeling in health and disease
2007 Standout
Treatment of postmenopausal osteoporosis
2002
Porosity of 3D biomaterial scaffolds and osteogenesis
2005 Standout
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature
2005
Extracellular matrix structure
2015 Standout
Denosumab in Postmenopausal Women with Low Bone Mineral Density
2006
The degree of mineralization is a determinant of bone strength: a study on human calcanei
2004
Current options for the management of postmenopausal osteoporosis
2011
The epidemiology of quantitative ultrasound: A review of the relationships with bone mass, osteoporosis and fracture risk
1997
The Collagen Family
2010 Standout
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease
2006
Bone mineralization density distribution in health and disease
2007
Constant mineralization density distribution in cancellous human bone
2003
Osteoporosis, bone mineral density and CKD–MBD: treatment considerations
2017
Chronic arthritis leads to disturbances in the bone collagen network
2010 StandoutNobel
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
2008
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
The bone mineralization density distribution as a fingerprint of the mineralization process
2007
Epidemiology of Vertebral Fractures
2015
RISK FACTORS FOR OSTEOPOROTIC FRACTURE
1998
Assessment of fracture risk
2004
Influence of remodeling on the mineralization of bone tissue
2009
Is Cortical Bone Hip? What determines Cortical Bone Properties?
2007
Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women
2010
Osteoporosis. Frequency, consequences, and risk factors
1996
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass
2005
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies
2009
On the mechanisms of biocompatibility
2008 Standout
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Emerging therapeutic concepts for muscle and bone preservation/building
2015
The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis
2004
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
2010
Special Invited Papers Section: Therapeutic Equivalence – Clinical Issues and Statistical Methodology in Noninferiority Trials
2005
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
2004
Chronic Kidney Disease
2016 Standout
Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development
2005
Nanoscale hydroxyapatite particles for bone tissue engineering
2011 Standout
Prevention of falls and consequent injuries in elderly people
2005 Standout
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Efficacy and Safety of Oral Weekly Ibandronate in the Treatment of Postmenopausal Osteoporosis
2003
Clinical consequences of vertebral fractures
1997
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club
2005
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
2008
Human and Parasitic Papain-Like Cysteine Proteases: Their Role in Physiology and Pathology and Recent Developments in Inhibitor Design
2002
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Is there Any Interest in Combining Treatments in Osteoporosis?
2005
Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis
2000 Standout
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
2004
Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta-Analyses
2004
Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration
2021 Standout
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
2003
Synchrotron Radiation Microtomography Allows the Analysis of Three-Dimensional Microarchitecture and Degree of Mineralization of Human Iliac Crest Biopsy Specimens: Effects of Etidronate Treatment
2002
Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
2012 Standout
Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents
2002
Noninvasive assessment of bone mineral and structure: State of the art
1996
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
2004
Interventions for enhancing medication adherence
2008 Standout
Structure and mechanical quality of the collagen–mineral nano-composite in bone
2004
Screening for Osteoporosis: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation
2010
Bone Density Variation and Its Effects on Risk of Vertebral Deformity in Men and Women Studied in Thirteen European Centers: The EVOS Study
1997
Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study
2005
Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
2005
Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis
2002
Emerging drugs for postmenopausal osteoporosis
2009
Interventions for enhancing medication adherence
2014 Standout
Estrogen and progestogen use in postmenopausal women
2008
Noninvasive In Vivo Monitoring of Bone Architecture Alterations in Hindlimb-Unloaded Female Rats Using Novel Three-Dimensional Microcomputed Tomography
2003
From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteoporosis
2010 Standout
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
2005
Guidelines for assessment of bone microstructure in rodents using micro–computed tomography
2010 Standout
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
2006 Standout
Nature’s hierarchical materials
2007 Standout
Use of Inhaled Corticosteroids and Risk of Fractures
2001 Standout
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective
2012
Alendronate Prevents Further Bone Loss in Renal Transplant Recipients
2001
The interpretation and utility of ultrasound measurements of bone
1996
The amazing osteocyte
2010 Standout
Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis
2001
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
2008
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling
2007 Standout
A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis
2002
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Quantitative Ultrasound Techniques for the Assessment of Osteoporosis: Expert Agreement on Current Status
1997
Works of John Yates being referenced
Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial
2002
Rapid Loss of Hip Fracture Protection After Estrogen Cessation: Evidence From the National Osteoporosis Risk Assessment
2004
Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Study
2002
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
2000
Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms
2000
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women
2001
Weekly administration of alendronate: Rationale and plan for clinical assessment
2000
Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study
2004
Predicting vertebral deformity using bone densitometry at various skeletal sites and calcaneus ultrasound
1995
Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis
2000
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
2000